推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-33632861

chinasupport@letpub.com

登录 注册 新注册优惠

OncoTargets and Therapy

2023年12月最新中科院分区表数据已经更新,欢迎查询! 如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

按期刊名首写字母查看 ONCOTARGETS THE最新评论:1.7号开始邀请审稿人。2.4号才邀请到一个,目前2.23号还没邀请到第二个。杂志要求一定要有2个以上审稿人,不知道还要多久 (2024-02-22)


期刊名:   ISSN:   研究方向:   影响因子: -   SCI收录:
大类学科:   小类学科:   中科院分区:   是否OA期刊:   结果排序:

同行评审状态查询 Manuscript Number * Last Name * First Name * 出版社 * 查 询 重 置

按研究方向查看:


OncoTargets and Therapy期刊基本信息Hello,您是该期刊的第150174位访客

基本信息 登录收藏
期刊名字OncoTargets and TherapyOncoTargets and Therapy

ONCOTARGETS THER
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
4.9
52人评分
我要评分

声誉
3.5

影响力
5.2

速度
9.2

期刊ISSN1178-6930
微信扫码收藏此期刊
2022-2023最新影响因子
(数据来源于搜索引擎)
4 点击查看影响因子趋势图
实时影响因子 截止2023年12月27日:2.278
2022-2023自引率0.00%点击查看自引率趋势图
五年影响因子3.7
h-index 44
CiteScore
CiteScoreSJRSNIPCiteScore排名
9.200.8360.753
学科分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q125 / 260
大类:Medicine
小类:Oncology
Q156 / 366

期刊简介
OncoTargets and Therapy is an international, peer-reviewed journal focusing on molecular aspects of cancer research, that is, the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.

The journal is characterized by the rapid reporting of high-quality original research, basic science, reviews and evaluations, expert opinion and commentary that shed novel insight on a cancer or cancer subtype.

Specific topics covered by the journal include:

-Novel therapeutic targets and innovative agents
-Novel therapeutic regimens for improved benefit and/or decreased side effects
-Early stage clinical trials

Further considerations when submitting to OncoTargets and Therapy:

-Studies containing in vivo animal model data will be considered favorably.
-Tissue microarray analyses will not be considered except in cases where they are supported by comprehensive biological studies involving multiple cell lines.
-Biomarker association studies will be considered only when validated by comprehensive in vitro data and analysis of human tissue samples.
-Studies utilizing publicly available data (e.g. GWAS/TCGA/GEO etc.) should add to the body of knowledge about a specific disease or relevant phenotype and must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Bioinformatics studies must be validated using the authors’ own data through replication in an independent sample set and functional follow-up.
-Single nucleotide polymorphism (SNP) studies will not be considered.
期刊官方网站https://www.dovepress.com/oncotargets-and-therapy-journal
期刊投稿网址https://www.dovepress.com/submit_step_1.php
期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足OncoTargets and Therapy的语言要求,还能让OncoTargets and Therapy编辑和审稿人得到更好的审稿体验,让稿件最大限度地被OncoTargets and Therapy编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢
提交文稿
是否OA开放访问Yes
OA期刊相关信息
文章处理费:需要( USD2310; )
文章处理费豁免:查看说明

其他费用:没有
期刊主题关键词:oncology、cancer、palliative care、therapeutic agents
相关链接:Aims & ScopeAuthor InstructionsEditorial BoardBlind peer review
通讯方式PO BOX 300-008, ALBANY, NEW ZEALAND, AUCKLAND, 0752
出版商Dove Medical Press Ltd.
涉及的研究方向BIOTECHNOLOGY & APPLIED MICROBIOLOGY-ONCOLOGY
出版国家或地区ENGLAND
出版语言English
出版周期
出版年份2008
年文章数 124点击查看年文章数趋势图
Gold OA文章占比97.88%
研究类文章占比:
文章 ÷(文章 + 综述)
63.71%
WOS期刊SCI分区
2022-2023年最新版
WOS分区等级:2区

按学科分区JIF分区JIF排名JIF百分位
学科:BIOTECHNOLOGY & APPLIED MICROBIOLOGY
类别:SCIE
Q255/156
学科:ONCOLOGY
类别:SCIE
Q296/241
中科院《国际期刊预警
名单(试行)》名单
2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:预警等级:中

2020年12月发布的2020版:预警等级:中
中科院SCI期刊分区
2023年12月最新升级版
点击查看中科院SCI期刊分区趋势图
大类学科小类学科Top期刊综述期刊
医学 1区4区1区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
生物工程与应用微生物
2区3区3区
ONCOLOGY
肿瘤学
4区1区4区
中科院SCI期刊分区
2022年12月升级版
大类学科小类学科Top期刊综述期刊
医学 1区3区1区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
生物工程与应用微生物
3区4区3区
ONCOLOGY
肿瘤学
3区1区4区
中科院SCI期刊分区
2021年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 4区4区1区
BIOTECHNOLOGY & APPLIED MICROBIOLOGY
生物工程与应用微生物
4区1区3区
ONCOLOGY
肿瘤学
4区2区4区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
Directory of Open Access Journals (DOAJ)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1178-6930%5BISSN%5D
平均审稿速度网友分享经验:
较慢,6-12周
平均录用比例网友分享经验:
较易
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在OncoTargets and Therapy顺利发表。
快看看作者怎么说吧:服务好评 论文致谢
期刊常用信息链接
同领域相关期刊 OncoTargets and Therapy期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 OncoTargets and Therapy中科院SCI期刊分区趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
OncoTargets and Therapy上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 中科院SCI期刊分区趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发表论文
  • 中科院SCI期刊分区相关期刊
  • 同类著名期刊名称 h-index CiteScore
    JAMA Oncology4144.30
    JAMA Oncology6144.30
    Nature Cancer020.80
    Trends in Cancer024.80
    Liver Cancer2516.90
    Experimental Hematology & Oncology09.50
    Annual Review of Cancer Biology021.00
    ESMO Open08.70
    Molecular Therapy-Oncolytics129.10
    Cancer Biology & Medicine297.90
    中科院SCI期刊分区同大类学科的热搜期刊 浏览次数
    MEDICINE599767
    BIOMATERIALS512635
    BIOMEDICINE & PHARMACOTHERAPY461752
    Journal of Materials Chemistry B458349
    Frontiers in Pharmacology448133
    Frontiers in Immunology419093
    JOURNAL OF ETHNOPHARMACOLOGY403511
    COLLOIDS AND SURFACES B-BIOINTERFACES403038
    Frontiers in Oncology382429
    Acta Biomaterialia374553
  •  

    OncoTargets and Therapy OncoTargets and Therapy
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.Successful Retreatment with Crizotinib After Crizotinib-Induced Liver Failure in ALK-Positive Advanced Lung Adenocarcinoma: A Case Report

    Author: Zhang, Xiangming; Ni, Kai; Chen, Huijun
    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 87-90. DOI: 10.2147/OTT.S393165
        PubMed      DOI
    2.Role of Systemic Immunoinflammation Landscape in the Overall Survival of Patients with Leptomeningeal Metastases from Lung Cancer

    Author: Wang, Jia-Wei; Yuan, Qing; Li, Li; Cao, Kai-Hua; Liu, Qi; Wang, Hong-Liang; Hu, Ke; Wu, Xi; Wan, Jing-Hai
    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 179-187. DOI: 10.2147/OTT.S402389
        PubMed      DOI
    3.Secondary Sinonasal Collision Tumor of Papillary Squamous Cell Carcinoma and Small Cell Neuroendocrine Carcinoma After Nasopharyngeal Carcinoma Radiotherapy: A Case Report and Literature Review of Sinonasal Collision Carcinomas

    Author: Tang, Hao; Wang, Lina; Xu, Wenfeng; Xu, Yujuan; Li, Xianyun; Guo, Deyu
    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 91-97. DOI: 10.2147/OTT.S396703
        PubMed      DOI
    4.Ineffectiveness of Crizotinib in a Non-Small-Cell Lung Cancer with Novel ALK-LIMS1 Fusion: A Case Report

    Author: Shi, Junmei; Jia, Zhaohui; Zhou, Zhiguo; Zhao, Liyan; Meng, Qingju; Liu, Yibing
    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 109-114. DOI: 10.2147/OTT.S388962
        PubMed      DOI
    5.Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study

    Author: Li, Guiling; Cheng, Mingxia; Hong, Kai; Jiang, Yao
    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 157-163. DOI: 10.2147/OTT.S400376
        PubMed      DOI
    6.A Primary Lung and Breast Cancer Patient with Germline EGFR R776H Mutation: A Case Report and Literature Review

    Author: Li, Dan; Liu, Xin; Cui, SaiQiong; Yang, DaFu; Zhu, Yue; Pan, Evenki; Yang, Peng; Dai, ZhaoXia
    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 17-22. DOI: 10.2147/OTT.S391766
        PubMed      DOI
    7.Transmission of Exosomal TPX2 Promotes Metastasis and Resistance of NSCLC Cells to Docetaxel

    Author: Hu, Jiaru; He, Qing; Tian, Tian; Chang, Na; Qian, Liting
    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 197-210. DOI: 10.2147/OTT.S401454
        PubMed      DOI
    8.A Refractory Case of CDKN2A/B Loss Metastatic Intrahepatic Cholangiocarcinoma Achieving a Partial Response After First-Line Treatment with Palbociclib

    Author: Fan, Weiming; Wang, Chuan; Zhong, Xuefeng; Zheng, Yating; Chen, Tingting; Huang, Mengli; Su, Shuying
    Journal: ONCOTARGETS AND THERAPY. 2023; Vol. 16, Issue , pp. 23-29. DOI: 10.2147/OTT.S390458
        PubMed      DOI
    9.Ribonucleotide reductase subunit M2 as a novel target for clear-cell renal cell carcinoma.

    Author: Zou Y1, Zhou J1, Xu B1, Li W1, Wang Z1.
    Journal: Onco Targets Ther. 2019 Apr 30;12:3267-3275. doi: 10.2147/OTT.S196347. eCollection 2019.
        PubMed      DOI
    10.MEX3C regulates lipid metabolism to promote bladder tumorigenesis through JNK pathway.

    Author: Chao H1, Deng L2, Xu F3, Yu Z2, Xu X2, Huang J2, Zeng T4.
    Journal: Onco Targets Ther. 2019 May 1;12:3285-3294. doi: 10.2147/OTT.S199667. eCollection 2019.
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144642.90
    LANCET700133.20
    NEW ENGLAND JOURNAL OF MEDICINE933134.40
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION62245.40
    NATURE REVIEWS DRUG DISCOVERY289123.80
    BMJ-British Medical Journal015.30
    BMJ-British Medical Journal015.30
    NATURE REVIEWS IMMUNOLOGY35183.00
    NATURE MEDICINE497107.50
    Nature Reviews Disease Primers4860.90
    同分区等级的其他期刊名称 h-index CiteScore
    HARVARD BUSINESS REVIEW02.40
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE1086.10
    Energy Material Advances08.50
    CLINICAL AND EXPERIMENTAL HYPERTENSION453.60
    Journal of Public Transportation07.00
    Asian Journal of Psychiatry010.90
    Chinese Journal of Population Resources and Environment02.60
    VIEW08.60
    HLA933.00
    INTERNATIONAL JOURNAL OF SOCIAL PSYCHIATRY011.50


以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:

    同领域作者分享投稿经验:共1243条 (包含回复)

我来分享

    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2024 中国: LetPub上海分公司    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960

    增值电信业务经营许可证:沪B2-20211595

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室

    United States: Tel: 1-781-202-9968 Address: 400 5th Ave, Suite 530, Waltham, Massachusetts 02451